Analyst Ratings For Aralez Pharmaceuticals (NASDAQ:ARLZ)
Today, HC Wainwright initiated coverage on Aralez Pharmaceuticals (NASDAQ:ARLZ) with a Buy with a price target of $6.00.
Some recent analyst ratings include
- 2/5/2018-HC Wainwright initiated coverage with a Buy rating.
- 4/10/2017-Bloom Burton Upgrade from a “Accumulate ” rating to a ” Buy” rating.
Recent Insider Trading Activity For Aralez Pharmaceuticals (NASDAQ:ARLZ)
Aralez Pharmaceuticals (NASDAQ:ARLZ) has insider ownership of 6.70% and institutional ownership of 19.45%.
- On 12/8/2017 Arthur S Kirsch, Director, bought 50,000 with an average share price of $1.47 per share and the total transaction amounting to $73,500.00.
- On 10/2/2017 James Patrick Tursi, Insider, sold 9,960 with an average share price of $2.50 per share and the total transaction amounting to $24,900.00.
- On 7/28/2017 Scott J Charles, CFO, sold 10,804 with an average share price of $1.25 per share and the total transaction amounting to $13,505.00.
- On 6/23/2017 Eric Trachtenberg, Insider, sold 7,720 with an average share price of $1.33 per share and the total transaction amounting to $10,267.60.
- On 6/15/2017 Arthur S Kirsch, Director, bought 15,000 with an average share price of $1.15 per share and the total transaction amounting to $17,250.00.
- On 6/14/2017 Arthur S Kirsch, Director, bought 50,000 with an average share price of $1.17 per share and the total transaction amounting to $58,500.00.
- On 6/5/2017 Andrew I Koven, Insider, sold 161,906 with an average share price of $1.28 per share and the total transaction amounting to $207,239.68.
Recent Trading Activity for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Shares of Aralez Pharmaceuticals closed the previous trading session at with 114925 shares trading hands.